Benefits
Blood pressure and fasting glucose: one 12-week extract trial
In a single trial, 102 adults with metabolic syndrome took 10 mg/day of an olive polyphenol extract that is mostly oleocanthal and oleacein, or a placebo, for 12 weeks. The extract group ended with lower fasting glucose (by 7.1 mg/dL), HbA1c (0.29 points) and systolic blood pressure (7.7 mmHg) than placebo. The product is a mixture, was registered after the trial ended, and has not been repeated.
Platelet activity after oleocanthal-rich olive oil meals
In two small crossover studies, olive oil rich in oleocanthal lowered platelet aggregation measured in blood drawn in the hours after one serving: 9 healthy men given 40 mL of oil, and 10 adults with type 2 diabetes given oil with 250 or 500 mg/kg oleocanthal. These were single servings and a lab measure, not a test of clots, bleeding or heart events.
Antioxidant markers in olive oil trials
In a one-month crossover of 91 adults with obesity and prediabetes, oil rich in oleocanthal and oleacein raised total antioxidant status and lowered lipid peroxides compared with common olive oil. In a small study of single meals in 10 adults with type 2 diabetes, oleocanthal-rich oil blunted the post-meal rise in a lipid oxidation marker. Both tested whole oils, not oleocanthal alone.
Inflammation markers: little change in people so far
In a one-month controlled crossover of 91 adults with inflammation as the primary outcome, only interferon-gamma differed between oleocanthal-rich and common olive oil (p = 0.041); no other marker reached a significant difference. A small study of 23 adults with no comparison group reported lower IL-6 and TNF-alpha after 2 months on high-oleocanthal oil. C-reactive protein was not among the 12-week extract trial's reported improvements.
No authorized health claim names oleocanthal
The EU lets olive oil state that olive oil polyphenols contribute to the protection of blood lipids from oxidative stress, only if it has at least 5 mg of hydroxytyrosol and its derivatives per 20 g and the effect is tied to 20 g of that oil daily. The claim covers the oil, does not name oleocanthal, and does not apply to capsules.
Mechanism of action
Cyclooxygenase-1 and -2 inhibition (in vitro)
In test-tube enzyme assays purified oleocanthal inhibits COX-1 and COX-2, the enzymes that make prostaglandins. Whether the amounts eaten in olive oil do this in people has not been shown, and in a human platelet crossover the authors' analysis suggested that cyclooxygenase blockade did not explain the platelet result they measured.
Amyloid transporters in mice, not in people
In cultured mouse brain endothelial cells and in normal C57BL/6 mice (not an Alzheimer's model), oleocanthal raised P-glycoprotein and LRP1 at the blood-brain barrier and sped clearance of injected radiolabelled amyloid-beta. No such measurement exists in people. A six-month trial in 25 people found less barrier leakage on MRI with an oleocanthal-rich olive oil but not refined oil.
Platelet aggregation, by a pathway that is not settled
In the two human crossover studies, oil rich in oleocanthal lowered platelet aggregation: collagen-stimulated aggregation two hours after the oil in 9 healthy men, and ADP- and thrombin-receptor-stimulated aggregation from 90 to 240 minutes after the meal in 10 people with type 2 diabetes. The fall tracked oleocanthal intake, but eicosanoid inhibition tracked total phenolic intake.
Other anti-inflammatory signalling: cell and animal work only
A review of olive oil phenolics describes anti-inflammatory and related activities for oleocanthal in cell and animal studies and concludes that intervention studies at realistic intakes in people are still needed. In a one-month controlled crossover in 91 adults with inflammation as the primary outcome, only interferon-gamma differed between oils.
Clinical trials
Double-blind, randomized, placebo-controlled trial of 10 mg/day of an olive oil polyphenol extract (two 5 mg capsules) for 12 weeks. The paper gives it as 80% oleocanthal plus oleacein and 18% oleuropein and ligstroside aglycones; the ClinicalTrials.gov entry (NCT07144488, posted August 2025 after the trial ended) names OLEOPROTECT, Thousand Olives and lists 75% and 25%. A mixture, not oleocanthal alone. (Samoutis et al. 2026, Clinical Nutrition ESPEN)
102 adults with metabolic syndrome; all 102 completed and were analysed.
Against placebo, fasting glucose fell by 7.06 mg/dL and HbA1c by 0.29 points (the primary outcomes), with lower BMI (1.15), systolic blood pressure (7.66 mmHg), triglycerides, oxidized LDL, uric acid and ALT. C-reactive protein, a secondary outcome, is not among the reported improvements. No serious adverse events. No independent replication has been published.
Randomized, double-blind crossover: participants replaced all raw and cooking oil for one month with an extra-virgin olive oil rich in oleocanthal and oleacein or a common olive oil, then switched. Tests whole oils, not oleocanthal alone; two producers donated the oils. (Ruiz-Garcia et al. 2023, Clinical Nutrition)
91 adults aged 40 to 65 with obesity and prediabetes (33 men, 58 women).
Inflammatory status was the primary outcome; of the markers measured only interferon-gamma differed between oils (p = 0.041). Total antioxidant status rose and lipid and organic peroxides fell compared with the common oil (p < 0.05). Weight, BMI and blood glucose fell during the rich-oil period only, not as a tested difference between the two oils.
Randomized, single-blind crossover of five isocaloric bread meals: butter, butter plus 400 mg ibuprofen as a positive control, 40 mL olive oil low in phenolics, or 40 mL olive oil with 250 or 500 mg/kg oleocanthal. Single meals of whole oil. A companion paper reported redox markers from the same 10 people. (Katsa et al. 2024, International Journal of Molecular Sciences)
10 adults with type 2 diabetes.
Platelet sensitivity to ADP (by 50 to 100%) and to TRAP (by 20 to 50%) fell in a dose-dependent way from 90 to 240 minutes after the oleocanthal meals, compared with the low-phenolic oil or butter meals. Glucose and lipid responses did not differ between meals. The companion paper found a blunted post-meal rise in TBARS. A lab measure, not a clinical event.
Randomized crossover: 40 mL of each of three extra-virgin olive oils matched for total phenolics, a week apart. Two contained 172 or 310 mg/kg oleocanthal; the third was mainly tyrosol. Blood drawn before and 2 hours after. Funding included Gaea Products S.A. (Agrawal et al. 2017, Journal of Functional Foods)
9 healthy men.
The two oleocanthal-containing oils lowered collagen-stimulated maximum platelet aggregation 2 hours after intake, and the fall correlated with oleocanthal intake (R = 0.56, p = 0.002). Eicosanoid inhibition tracked total phenolic intake instead, and the authors suggested cyclooxygenase blockade was not responsible for the platelet effect. Five of the nine men had falls above 25%.
Randomized trial of 30 mL a day of an extra-virgin olive oil (1200 mg/kg total polyphenols, including 621 mg/kg oleocanthal and 344 mg/kg oleacein) or refined olive oil for 6 months. Whole oil, not oleocanthal alone; the corresponding author is a co-founder and equity shareholder in Oleolive, LLC. (Kaddoumi et al. 2022, Nutrients)
26 adults with mild cognitive impairment randomized, 25 completed (13 extra-virgin, 12 refined).
Blood-brain-barrier permeability on contrast MRI fell and functional connectivity rose with the extra-virgin oil but not the refined oil (the primary outcomes). Clinical dementia rating and behavioural scores improved on both oils, and both lowered blood amyloid-beta 42/40 and p-tau/t-tau ratios. A 25-person proof-of-concept study.
Open-label, single-arm study with no control group: 32 g a day (4 large spoons) of a mono-cultivar extra-virgin olive oil described as high in oleocanthal, for 60 days, with no other oil allowed. The paper does not report the oil's oleocanthal content. Whole oil; university research funds only. (Patti et al. 2020, Metabolites)
23 adults with metabolic syndrome and hepatic steatosis on ultrasound (15 men, 8 women, mean age 60).
Compared with their own baseline, body weight, waist circumference, BMI and the liver enzyme ALT fell, and the cytokines IL-6, IL-17A, TNF-alpha and IL-1B fell while IL-10 rose. Plasma lipids, fasting glucose and HbA1c did not change significantly. With no comparison group, these before-and-after changes cannot be attributed to the oil.